Epidemiologic and molecular prognostic review of glioblastoma
- PMID: 25053711
- PMCID: PMC4185005
- DOI: 10.1158/1055-9965.EPI-14-0275
Epidemiologic and molecular prognostic review of glioblastoma
Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous system malignancy with a median survival of 15 months. The average incidence rate of GBM is 3.19/100,000 population, and the median age of diagnosis is 64 years. Incidence is higher in men and individuals of white race and non-Hispanic ethnicity. Many genetic and environmental factors have been studied in GBM, but the majority are sporadic, and no risk factor accounting for a large proportion of GBMs has been identified. However, several favorable clinical prognostic factors are identified, including younger age at diagnosis, cerebellar location, high performance status, and maximal tumor resection. GBMs comprise of primary and secondary subtypes, which evolve through different genetic pathways, affect patients at different ages, and have differences in outcomes. We report the current epidemiology of GBM with new data from the Central Brain Tumor Registry of the United States 2006 to 2010 as well as demonstrate and discuss trends in incidence and survival. We also provide a concise review on molecular markers in GBM that have helped distinguish biologically similar subtypes of GBM and have prognostic and predictive value.
©2014 American Association for Cancer Research.
Conflict of interest statement
Figures






Similar articles
-
A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999.Cancer. 2005 Dec 15;104(12):2798-806. doi: 10.1002/cncr.21539. Cancer. 2005. PMID: 16288487
-
Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.J Neurooncol. 2016 Apr;127(2):355-62. doi: 10.1007/s11060-015-2046-0. Epub 2016 Jan 2. J Neurooncol. 2016. PMID: 26725096
-
Comparative epidemiology of gliosarcoma and glioblastoma and the impact of Race on overall survival: A systematic literature review.Clin Neurol Neurosurg. 2020 Aug;195:106054. doi: 10.1016/j.clineuro.2020.106054. Epub 2020 Jun 29. Clin Neurol Neurosurg. 2020. PMID: 32650210
-
Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis.Neuro Oncol. 2009 Dec;11(6):833-41. doi: 10.1215/15228517-2008-123. Neuro Oncol. 2009. PMID: 19332771 Free PMC article.
-
Long-Term Time Series Forecasting and Updates on Survival Analysis of Glioblastoma Multiforme: A 1975-2018 Population-Based Study.Neuroepidemiology. 2022;56(2):75-89. doi: 10.1159/000522611. Epub 2022 Feb 16. Neuroepidemiology. 2022. PMID: 35172317 Review.
Cited by
-
A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study.BMC Surg. 2021 May 6;21(1):238. doi: 10.1186/s12893-021-01233-z. BMC Surg. 2021. PMID: 33957923 Free PMC article.
-
Targeting Intracranial Tumours with a Combination of RNA and Chemotherapy.Pharmaceutics. 2024 Jun 18;16(6):829. doi: 10.3390/pharmaceutics16060829. Pharmaceutics. 2024. PMID: 38931949 Free PMC article.
-
The use of external control data for predictions and futility interim analyses in clinical trials.Neuro Oncol. 2022 Feb 1;24(2):247-256. doi: 10.1093/neuonc/noab141. Neuro Oncol. 2022. PMID: 34106270 Free PMC article.
-
Combination of US hyperthermia and radiotherapy on a preclinical glioblastoma model.Sci Rep. 2024 Aug 27;14(1):19878. doi: 10.1038/s41598-024-70838-0. Sci Rep. 2024. PMID: 39191985 Free PMC article.
-
Gliomas display distinct sex-based differential methylation patterns based on molecular subtype.Neurooncol Adv. 2020 Jan 8;2(1):vdaa002. doi: 10.1093/noajnl/vdaa002. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 32642674 Free PMC article.
References
-
- Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci. 2010;17:417–421. - PubMed
-
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical